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Abstract
The most recent updated classification of inborn errors of immunity/primary immunodeficiencies, compiled by the International
Union of Immunological Societies Expert Committee, was published in January 2020. Within days of completing this report, it
was already out of date, evidenced by the frequent publication of genetic variants proposed to cause novel inborn errors of
immunity. As the next formal report from the IUIS Expert Committee will not be published until 2022, we felt it important to
provide the community with a brief update of recent contributions to the field of inborn errors of immunity. Herein, we highlight
studies that have identified 26 additional monogenic gene defects that reach the threshold to represent novel causes of immune
defects.
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Introduction
Inborn errors of immunity (IEI) are generally considered to
result from monogenic germline defects that manifest as in-
creased susceptibility to severe and/or recurrent infectious dis-
eases, autoimmune or autoinflammatory conditions, atopic
manifestations, and hematopoietic or solid tissuemalignancies
[1]. Over the past decade, the discovery of new IEIs has been
occurring at an impressive rate. Indeed, the 2011 biennial
update published by the IUIS Committee update listed 191
IEIs; this number increased to 430 in the 2019 update [2, 3].
This near-exponential increase in gene discovery is being
driven by the accessibility and affordability of next-
generation sequencing, and the efficient application of these
technologies to elucidate the molecular etiology of unsolved
cases of IEIs that are likely to result from single-gene defects
[4].
Over the last 12 months, we have witnessed the ongoing
rapid identification, and occasionally detailed molecular,
biochemical, and cellular characterization, of genetic variants
that cause, or are at least associated with, human diseases
impacting host defense or immune regulation. Here, we will
summarize reports on variants detected in 26 genes which we
consider represent novel IEI (Table 1). Many additional ge-
netic variants have been reported recently. However, those
listed here have been adjudicated by the IUIS Committee to
meet the strict criteria to be considered disease-causing [57].
These criteria include:
1. The patient’s candidate genotype is monogenic and must
not occur in individuals without the clinical phenotype;
2. Experimental studies must indicate the genetic variant im-
pairs, destroys, or alters expression or function of the gene
product;
3. The causal relationship between the candidate genotype
and the clinical phenotype must be confirmed via a rele-
vant cellular phenotype, including—where possible—res-
cue of a functional defect by reconstitution with the wild-
type gene, or via a relevant animal phenotype [57].
We also considered (i) the numbers of individuals affected
by the novel variants, (ii) sufficient justification for excluding
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alternative candidate gene variants identified in single cases
especially in situations of consanguinity with recessive dis-
ease, (iii) the depth of the clinical descriptions of affected
individuals, and (iv) the level of immune and mechanistic
characterization.
Novel Causes of Inborn Errors of Immunity
Currently, inborn errors of immunity are listed in 10
tables: Immunodeficiencies affecting cellular and humor-
al immunity (Table I), Combined immunodeficiencies
(C ID ) w i t h s y n d r om i c f e a t u r e s ( T a b l e I I ) ,
Predominantly antibody deficiencies (Table III),
Diseases of immune dysregulat ion (Table IV),
Congenital defects of phagocytes (Table V), Defects in
i n t r i n s i c a n d i n n a t e immun i t y ( T a b l e V I ) ,
Autoinflammatory diseases (Table VII), Complement de-
ficiencies (Table VIII), Bone Marrow failure (Table IX),
and Phenocopies of inborn errors of immunity
(Table X). Several of these tables are further partitioned
into various subtables (e.g., Table I is split into
Sub t ab l e 1 [T−B+ Seve re Combined Immune
Deficiency (SCID)], Subtable 2 [T−B− SCID] and
Subtable 3 [CID, generally less profound than SCID])
[2, 3].
Recently-reported gene defects have been found for most
categories of inborn errors of immunity, including novel
causes of:
& SCID (PAX1 [5, 6], SLP76 [7]);
& CID (MCM10 [8], IL6ST [9–11]);
& Predominantly antibody deficiencies (FNIP1 [14, 15],
PIK3CG [16, 17], CTNNBL1 [18], TNFSF13 [19]);
& Autoinflammatory diseases (SOCS1 [20–22], TET2 [23],
CEBPE [24], CDC42 [33–39], LSM11, RNU7–1 [32],
STAT2 [40, 41], RIPK1 [42, 43], NCKAP1L [44–46]),
UBA1 (somatic mutations) [47]; and
& Susceptibility to infection with specific pathogens
(MAPK8 [31]; TBX21 [25], IFNG [26], NOS2 [28],
SNORA31 [29], ATG4A, MAP1LC3B2 [30]) (Table 1).
Notably, several of these genes are already included in
previous IUIS updates, namely IL6ST, STAT2, CEBPE, and
RIPK1 [2, 3]. However, they are listed here because the var-
iant identified is pathogenic via a distinct mechanism and/or
different mode of inheritance; i.e., autosomal recessive (AR)
vs autosomal dominant for IL6ST [9] or RIPK1 [42, 43], par-
tial deficiency vs complete deficiency for IL6ST [10, 11], or
AR loss of function vs AR gain of function for CEBPE [24] or
STAT2 [40, 41]. Furthermore, the GOF variants reported for
CEBPE appear to represent the first described germline
neomorphic mutation in inborn errors of immunity where
the variant allele has completely novel functions not seen for
the wild type gene [24]. Thus, these findings underscore the
importance of appropriately interpreting genetic variants iden-
tified by next-generation sequencing, not discarding variants
of unknown significance simply because they do not match
the expected zygosity or clinical phenotype of previously re-
ported studies, and to rigorously validate the impact of novel
variants on the function of the encoded protein.
Joining the Dots with Discoveries of Novel
Inborn Errors of Immunity
Many known inborn errors of immunity impact a de-
fined signaling pathway such that mutations in compo-
nents of these same pathways can represent clinical
phenocopies of diseases causes by distinct genetic vari-
ants (genetic heterogeneity). In other words, physiolog-
ical homogeneity can be identified for many genotypes
underlying a given phenotype. Classic examples of this
are Mendelian susceptibility to mycobacterial disease
(MSMD), which results from impaired IFNγ-mediated
immunity following exposure to mycobacterial species
[58], and herpes simplex virus encephalitis (HSE)
resulting from impaired TLR3-mediated anti-HSV1 im-
munity [59, 60]. Thus, variants in genes affecting the
production of IFNγ (e.g., IL12RB1, IL12RB2, IL23R,
TYK2, IKBKG, SPPL2A, IRF8) or cellular responses
to IFNγ (e.g., IFNGR1, IFNGR2, STAT1, JAK1) result
in MSMD in otherwise healthy individuals [58].
Similarly, inactivating mutations in signaling compo-
nents of the TLR3 signaling pathway (TLR3, UNC93B,
TRIF, TRAF3, TBK1, IRF3) underlie HSE due to im-
paired type 1 IFN-mediated central nervous system
(CNS) intrinsic immunity against HSV1 [59, 60].
Recent discoveries have further linked common clin-
ical phenotypes with unique genotypes that converge in
a shared pathway. Thus, the non-redundant role of
IFNγ-mediated immunity in host defense against myco-
bacterial infection [58] has been definitively established
by the identification of individuals with inactivating bi-
allelic mutations in not only IFNG itself [26] but also
TBX21 [25], the transcription factor that regulates ex-
pression and production of IFNγ.
Interestingly, variants in the small nucleolar RNA
SNORA31 predispose affected individuals to HSE.
Mechanistically, patient’s iPSC-derived cortical neurons were
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found to be highly susceptible to HSV-1 infection in vitro, and
this could be restored by exogenous IFNβ [29, 60]. However,
responses of these cells to TLR3 and IFNβ, but not HSV1, are
intact, revealing that SNORA31 functions to regulate cell-
intrinsic immunity to HSV-1 by a mechanism independent
of TLR3 signaling [29, 60]. The discovery of individuals with
SNORA31 variants will facilitate further understanding of
CNS-intrinsic host defense.
The discoveries of individuals with complete gp130-
deficiency due to null/nonsense bi-allelic mutations of
IL6ST [11], or pathogenic dominant-negative heterozy-
gous variants of IL6ST [9], and a phenotype of eczema,
hyper-IgE, and eosinophilia, likely explain these features
of autosomal dominant hyper-IgE syndrome due to
STAT3 negative dominance [61] and further highlight
the role of IL-6 signaling in restraining atopic and al-
lergic responses. Furthermore, the lack of mucocutane-
ous candidiasis in patients with impaired signaling via
receptors for IL-6 (IL6R, IL6ST mutations [9, 11, 50,
62, 63]; anti-IL-6 autoantibodies [64]), IL-23 (biallelic
IL23R variants) [65] or IL-21 (biallelic IL21 or IL21R
variants) [66] argues that individually these cytokines
are not required for the STAT3-mediated generation of
human Th17 cells and host defense against fungal in-
fections. Rather, the combinatorial defect of impaired
STAT3 signaling downstream of these receptors ex-
plains chronic mucocutaneous candidiasis in an individ-
ual with dominant-negative STAT3 mutations. These
findings again reveal the capacity for inborn errors of
immunity to provide convincing evidence for basic im-
munological concepts. Indeed, this is further exemplified
by the d i scovery tha t va r i an t s o f ATG4A or
MAP1LC3B2 cause recurrent HSV2 infection of the
CNS, thereby establishing hitherto non-redundant func-
tions of the autophagy pathway in non-hematopoietic
cell-mediated intrinsic anti-viral immune responses [30].
SARS-CoV2 and Inborn Errors of Immunity
The COVID19 pandemic of 2020 has clearly changed the
world in many ways. It has also yielded opportunities to
understand host requirements for immunity against
SARS-CoV2 infection. A recent study of ~ 650 individ-
uals who developed severe COVID-19 found that ~ 3.5%
of patients harbored germline loss-of-function variants in
genes previously found to be important for host defense
against influenza or other viral infections (e.g., bi-allelic
loss of function mutations of IRF7 or IFNAR1, heterozy-
gous mutations in TLR3, TICAM1, TBK1, or IRF3) [67]
due to the key role of these genes in the type 1 IFN
signaling pathway [59, 68]. An accompanying study
found that, strikingly, ~ 10% of patients with severe
COVID-19 have high levels of neutralizing autoanti-
bodies (autoAbs) against type 1 IFNs in their serum
[48]. The impact of these autoAbs was evidenced by the
inability to detect IFN in serum from these patients, and
their capacity to prevent anti-viral immune responses
in vitro [48] (Table 1). These studies defined a crucial
and non-redundant role for type 1 IFNs in immune control
of SARS-CoV2 infection, and thus prevention of severe
COVID-19. Furthermore, they also established that
autoAbs against type 1 IFN phenocopy an inborn error
of immunity, as previously determined for autoAbs
against IFNγ and susceptibility to mycobacterial disease,
anti-Th17 cytokine (IL-17A, IL-17F, IL-22) autoAbs in
individuals with chronic mucocutaneous candidiasis, or
pyogenic infections due to anti-IL-6 autoAbs [64, 69].
Conclusions
Discoveries over the past 12 months in the field of
inborn errors of immunity have further identified non-
redundant functions of key genes in human immune cell
development, host defense, and immune regulation. In
some cases, these functions go well beyond what may
have been expected or anticipated based on animal
models (e.g., TBX21 [25]). They have also already
highlighted the heterogenous phenotypes that can result
from variants in the same gene (e.g., CDC42 [33–39,
52]), indicated that significant diseases can arise from
mono-allelic or bi-allelic loss of function (IL6ST [9],
RIPK1 [42, 43]) or bi-allelic loss- or gain-of-function
(CEBPE [24], STAT2 [40, 41]) variants in the same
gene, or from autoAb phenocopies of monogenic lesions
(e.g., COVID19 and anti-IFN Abs) [48], and identified
novel somatic mutations as pathogenic causes of im-
mune disorders (UBA1) [47]. Importantly, they have al-
so provided opportunities for therapeutic interventions,
such as JAK inhibitors to treat STAT2 gain of function
[40, 41] or SOCS1 deficiency [22], IFNγ to treat my-
cobacterial disease [25, 26], or early IFN-β or IFN-α2a
treatment of SARS-CoV2 infection in COVID-19 pa-
tients with autoantibodies against IFN-α or IFN-ω
[67] or impaired type 1 IFN responses [70]. This snap-
shot of genetic discoveries underpinning human immune
disorders further highlights the critical contributions of
inborn errors of immunity to our broader understanding
of basic, translational, and clinical immunology.

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































675J Clin Immunol  (2021) 41:666–679
Authors Contribution SGT wrote the drafts of the manuscript, prepared
the table, and revised the original manuscripts for resubmission. All co-
authors contributed to and edited drafts of the original and revised man-
uscripts and table, and approved the final submitted version.
Funding The members of the Inborn Errors of Immunity committee
would like to thank the International Union of Immunological Societies
for funding, as well as CSL Behring, Baxalta, and Shire/Takeda for pro-
viding educational grants to enable us to compile this interim update to
novel causes of immune diseases. This work was also supported in part by
the Intramural Research Program of the NIAID, NIH. SGT is supported
by an Investigator Grant (Level 3) awarded by the National Health and
Medical Research Council of Australia. IM is a senior clinical investiga-
tor of FWO Vlaanderen (EBD-D8974-FKM).
Data Availability Not applicable.
Declarations
Ethics Approval This work is a review of recently-reported genetic var-
iants that represent novel inborn errors of immunity. No human research
studies were performed in order to produce this review. Thus, no ap-
provals by appropriate institutional review boards or human research
ethics committees were required to undertake the preparation of this
report.
Consent to Participate Not applicable as this is a review of recently-
reported genetic variants.
Consent for Publication The authors consent to publish the content of
this review. However, as noted above, as this is a review of recently-
reported genetic variants that represent novel inborn errors of immunity,
we did not require consent to publish from participants.
Conflict of Interest The authors declare that they have no conflict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Notarangelo LD, Bacchetta R, Casanova JL, SuHC. Human inborn
errors of immunity: an expanding universe. Sci Immunol.
2020;5(49):eabb1662. https://doi.org/10.1126/sciimmunol.
abb1662.
2. Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T,
et al. Human inborn errors of immunity: 2019 update of the IUIS
phenotypical classification. J Clin Immunol. 2020;40(1):66–81.
https://doi.org/10.1007/s10875-020-00758-x.
3. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-
Rundles C, Etzioni A, et al. Human inborn errors of immunity:
2019 update on the Classification from the International Union of
Immunological Societies Expert Committee. J Clin Immunol.
2020;40(1):24–64. https://doi.org/10.1007/s10875-019-00737-x.
4. Meyts I, Bosch B, Bolze A, Boisson B, Itan Y, Belkadi A, et al.
Exome and genome sequencing for inborn errors of immunity. J
Allergy Clin Immunol. 2016;138(4):957–69. https://doi.org/10.
1016/j.jaci.2016.08.003.
5. Yamazaki Y, Urrutia R, Franco LM, Giliani S, Zhang K, Alazami
AM, et al. PAX1 is essential for development and function of the
human thymus. Sci Immunol. 2020;5(44):eaax1036. https://doi.
org/10.1126/sciimmunol.aax1036.
6. Paganini I, Sestini R, Capone GL, Putignano AL, Contini E, Giotti
I, et al. A novel PAX1 null homozygous mutation in autosomal
recessive otofaciocervical syndrome associated with severe com-
bined immunodeficiency. Clin Genet. 2017;92(6):664–8. https://
doi.org/10.1111/cge.13085.
7. Lev A, Lee YN, Sun G, Hallumi E, Simon AJ, Zrihen KS, et al.
Inherited SLP76 deficiency in humans causes severe combined
immunodeficiency, neutrophil and platelet defects. J Exp Med.
2021;218(3):e20201062. https://doi.org/10.1084/jem.20201062.
8. Mace EM, Paust S, Conte MI, Baxley RM, Schmit MM, Patil SL,
et al. Human NK cell deficiency as a result of biallelic mutations in
MCM10. J Clin Invest. 2020;130:5272–86. https://doi.org/10.
1172/JCI134966.
9. Beziat V, Tavernier SJ, Chen YH,Ma CS, MaternaM, Laurence A,
et al. Dominant-negative mutations in human IL6ST underlie
hyper-IgE syndrome. J Exp Med. 2020;217(6):e20191804. https://
doi.org/10.1084/jem.20191804.
10. Monies D, Abouelhoda M, Assoum M, Moghrabi N, Rafiullah R,
Almontashiri N, et al. Lessons learned from large-scale, first-tier
clinical exome sequencing in a highly consanguineous population.
Am J Hum Genet. 2019;104(6):1182–201. https://doi.org/10.1016/
j.ajhg.2019.04.011.
11. Chen YH, Grigelioniene G, Newton PT, Gullander J, Elfving M,
Hammarsjo A, et al. Absence of GP130 cytokine receptor signaling
causes extended Stuve-Wiedemann syndrome. J Exp Med.
2020;217(3):e20191306. https://doi.org/10.1084/jem.20191306.
12. Park H, Staehling K, Tsang M, Appleby MW, Brunkow ME,
Margineantu D, et al. Disruption of Fnip1 reveals a metabolic
checkpoint controlling B lymphocyte development. Immunity.
2012;36(5):769–81. https://doi.org/10.1016/j.immuni.2012.02.
019.
13. Siggs OM, Stockenhuber A, Deobagkar-Lele M, Bull KR,
Crockford TL, Kingston BL, et al. Mutation of Fnip1 is associated
with B-cell deficiency, cardiomyopathy, and elevated AMPK ac-
tivity. Proc Natl Acad Sci U S A. 2016;113(26):E3706–15. https://
doi.org/10.1073/pnas.1607592113.
14. Niehues T, Ozgur TT, Bickes M,Waldmann R, Schoning J, Brasen
J, et al. Mutations of the gene FNIP1 associated with a syndromic
autosomal recessive immunodeficiency with cardiomyopathy and
pre-excitation syndrome. Eur J Immunol. 2020;50(7):1078–80.
https://doi.org/10.1002/eji.201948504.
15. Saettini F, Poli C, Vengoechea J, Bonanomi S, Orellana JC, Fazio G,
et al. Absent B cells, agammaglobulinemia, and hypertrophic cardio-
myopathy in folliculin interacting protein 1 deficiency. Blood.
2021;137:493–9 https://doi.org/10.1182/blood.2020006441.
16. Takeda AJ, Maher TJ, Zhang Y, Lanahan SM, Bucklin ML,
Compton SR, et al. Human PI3Kgamma deficiency and its
microbiota-dependent mouse model reveal immunodeficiency and
tissue immunopathology. Nat Commun. 2019;10(1):4364. https://
doi.org/10.1038/s41467-019-12311-5.
17. Thian M, Hoeger B, Kamnev A, Poyer F, Kostel Bal S, Caldera M,
et al. Germline biallelic PIK3CG mutations in a multifaceted
676 J Clin Immunol  (2021) 41:666–679
immunodeficiency with immune dysregulation. Haematologica.
2020;105:e488. https://doi.org/10.3324/haematol.2019.231399.
18. Kuhny M, Forbes LR, Cakan E, Vega-Loza A, Kostiuk V, Dinesh
RK, et al. Disease-associated CTNNBL1 mutation impairs somatic
hypermutation by decreasing nuclear AID. J Clin Invest.
2020;130(8):4411-4422. https://doi.org/10.1172/JCI131297.
19. Yeh TW, Okano T, Naruto T, YamashitaM, OkamuraM, Tanita K,
et al. APRIL-dependent life-long plasmacyte maintenance and im-
munoglobulin production in humans. J Allergy Clin Immunol.
2020;146:1109–1120.e4. https://doi.org/10.1016/j.jaci.2020.03.
025.
20. Lee PY, Platt CD, Weeks S, Grace RF, Maher G, Gauthier K, et al.
Immune dysregulation and multisystem inflammatory syndrome in
children (MIS-C) in individuals with haploinsufficiency of SOCS1.
J Allergy Clin Immunol. 2020;146(5):1194–1200.e1. https://doi.
org/10.1016/j.jaci.2020.07.033.
21. Thaventhiran JED, Lango Allen H, Burren OS, Rae W, Greene D,
Staples E, et al. Whole-genome sequencing of a sporadic primary
immunodeficiency cohort. Nature. 2020;583(7814):90–5. https://
doi.org/10.1038/s41586-020-2265-1.
22. Hadjadj J, Castro CN, Tusseau M, Stolzenberg MC, Mazerolles F,
Aladjidi N, et al. Early-onset autoimmunity associated with SOCS1
haploinsufficiency. Nat Commun. 2020;11(1):5341. https://doi.org/
10.1038/s41467-020-18925-4.
23. Stremenova Spegarova J, Lawless D, Mohamad SMB, Engelhardt
KR, Doody G, Shrimpton J, et al. Germline TET2 loss of function
causes childhood immunodeficiency and lymphoma. Blood.
2020;136(9):1055–66. https://doi.org/10.1182/blood.2020005844.
24. Goos H, Fogarty CL, Sahu B, Plagnol V, Rajamaki K, Nurmi K,
et al. Gain-of-function CEBPE mutation causes noncanonical
autoinflammatory inflammasomopathy. J Allergy Clin Immunol.
2019;144(5):1364–76. https://doi.org/10.1016/j.jaci.2019.06.003.
25. Yang R,Mele F,Worley L, Langlais D, Rosain J, Benhsaien I, et al.
Human T-bet governs innate and innate-like adaptive IFN-gamma
immunity against mycobacteria. Cell. 2020;183(7):1826–1847.e31.
https://doi.org/10.1016/j.cell.2020.10.046.
26. Kerner G, Rosain J, Guerin A, AlKhabaz A, Oleaga-Quintas C,
Rapaport F, et al. Inherited human IFNgamma deficiency underlies
mycobacterial disease. J Clin Invest. 2020;130(6):3158–71. https://
doi.org/10.1172/JCI135460.
27. Noda S, Tanaka K, Sawamura S, Sasaki M, Matsumoto T, Mikami
K, et al. Role of nitric oxide synthase type 2 in acute infection with
murine cytomegalovirus. J Immunol. 2001;166(5):3533–41.
https://doi.org/10.4049/jimmunol.166.5.3533.
28. Drutman SB, Mansouri D, Mahdaviani SA, Neehus AL, Hum D,
Bryk R, et al. Fatal Cytomegalovirus infection in an adult with
inherited NOS2 deficiency. N Engl J Med. 2020;382(5):437–45.
https://doi.org/10.1056/NEJMoa1910640.
29. Lafaille FG, Harschnitz O, Lee YS, Zhang P, HasekML, Kerner G,
et al. Human SNORA31 variations impair cortical neuron-intrinsic
immunity to HSV-1 and underlie herpes simplex encephalitis. Nat
Med. 2019;25(12):1873–84. https://doi.org/10.1038/s41591-019-
0672-3.
30. Hait AS, Olagnier D, Sancho-Shimizu V, Skipper KA, Helleberg
M, Larsen SM, et al. Defects in LC3B2 and ATG4A underlie HSV2
meningitis and reveal a critical role for autophagy in antiviral de-
fense in humans. Sci Immunol. 2020;5(54):eabc2691. https://doi.
org/10.1126/sciimmunol.abc2691.
31. Li J, Ritelli M, Ma CS, Rao G, Habib T, Corvilain E, et al. Chronic
mucocutaneous candidiasis and connective tissue disorder in
humans with impaired JNK1-dependent responses to IL-17A/F
and TGF-beta. Sci Immunol. 2019;4(41):eabc2691. https://doi.
org/10.1126/sciimmunol.aax7965.
32. Uggenti C, Lepelley A, Depp M, Badrock AP, Rodero MP, El-
Daher MT, et al. cGAS-mediated induction of type I interferon
due to inborn errors of histone pre-mRNA processing. Nat Genet.
2020;52(12):1364–72. https://doi.org/10.1038/s41588-020-00737-
3.
33. Verboon JM, Mahmut D, Kim AR, Nakamura M, Abdulhay NJ,
Nandakumar SK, e t a l . Infant i le myelof ibros is and
myeloproliferation with CDC42 dysfunction. J Clin Immunol.
2020;40:554–66. https://doi.org/10.1007/s10875-020-00778-7.
34. Lam MT, Coppola S, Krumbach OHF, Prencipe G, Insalaco A,
Cifaldi C, et al. A novel disorder involving dyshematopoiesis, in-
flammation, and HLH due to aberrant CDC42 function. J ExpMed.
2019;216(12):2778–99. https://doi.org/10.1084/jem.20190147.
35. Gernez Y, de Jesus AA, Alsaleem H, Macaubas C, Roy A, Lovell
D, et al. Severe autoinflammation in 4 patients with C-terminal
variants in cell division control protein 42 homolog (CDC42) suc-
cessfully treated with IL-1beta inhibition. J Allergy Clin Immunol.
2019;144(4):1122–5 e6. https://doi.org/10.1016/j.jaci.2019.06.017.
36. Bucciol G, Pillay B, Casas-Martin J, Delafontaine S, Proesmans M,
Lorent N, et al. Systemic inflammation and myelofibrosis in a pa-
tient with Takenouchi-Kosaki syndrome due to CDC42 Tyr64Cys
mutation. J Clin Immunol. 2020;40:567–70. https://doi.org/10.
1007/s10875-020-00742-5.
37. Bekhouche B, Tourville A, Ravichandran Y, Tacine R, Abrami L,
Dussiot M, et al. A toxic palmitoylation of Cdc42 enhances NF-
kappaB signaling and drives a severe autoinflammatory syndrome.
J Allergy Clin Immunol. 2020;146(5):1201–1204.e8. https://doi.
org/10.1016/j.jaci.2020.03.020.
38. He T, Huang Y, Ling J, Yang J. A new patient with NOCARH
syndrome due to CDC42 defect. J Clin Immunol. 2020;40(4):571–
5. https://doi.org/10.1007/s10875-020-00786-7.
39. Szczawinska-Poplonyk A, Ploski R, Bernatowska E, Pac M. A
novel CDC42 mutation in an 11-year old child manifesting as
syndromic immunodeficiency, autoinflammation, hemophagocytic
lymphohistiocytosis, and malignancy: a case report. Front
Immunol. 2020;11:318. https://doi.org/10.3389/fimmu.2020.
00318.
40. Gruber C, Martin-Fernandez M, Ailal F, Qiu X, Taft J, Altman J,
et al. Homozygous STAT2 gain-of-function mutation by loss of
USP18 activity in a patient with type I interferonopathy. J Exp
Med. 2020;217(5):e20192319. https://doi.org/10.1084/jem.
20192319.
41. Duncan CJA, ThompsonBJ, Chen R, Rice GI, Gothe F, YoungDF,
et al. Severe type I interferonopathy and unrestrained interferon
signaling due to a homozygous germline mutation in STAT2. Sci
Immunol. 2019;4(42):eaav7501. https://doi.org/10.1126/
sciimmunol.aav7501.
42. Tao P, Sun J, Wu Z, Wang S, Wang J, Li W, et al. A dominant
autoinflammatory disease caused by non-cleavable variants of
RIPK1. Nature. 2020;577(7788):109–14. https://doi.org/10.1038/
s41586-019-1830-y.
43. Lalaoui N, Boyden SE, Oda H, Wood GM, Stone DL, Chau D,
et al. Mutations that prevent caspase cleavage of RIPK1 cause
autoinflammatory disease. Nature. 2020;577(7788):103–8. https://
doi.org/10.1038/s41586-019-1828-5.
44. Cook SA, Comrie WA, Poli MC, Similuk M, Oler AJ, Faruqi AJ,
et al. HEM1 deficiency disrupts mTORC2 and F-actin control in
inherited immunodysregulatory disease. Science. 2020;369(6500):
202–7. https://doi.org/10.1126/science.aay5663.
45. Salzer E, Zoghi S, Kiss MG, Kage F, Rashkova C, Stahnke S, et al.
The cytoskeletal regulator HEM1 governs B cell development and
prevents autoimmunity. Sci Immunol. 2020;5(49):eabc3979.
https://doi.org/10.1126/sciimmunol.abc3979.
46. Castro CN, Rosenzwajg M, Carapito R, Shahrooei M, Konantz M,
Khan A, et al. NCKAP1L defects lead to a novel syndrome com-
bining immunodef ic iency, lymphoprol i fera t ion, and
hyperinflammation. J Exp Med. 2020;217(12):e20192275. https://
doi.org/10.1084/jem.20192275.
677J Clin Immunol  (2021) 41:666–679
47. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei
W, et al. Somatic mutations in UBA1 and severe adult-onset
autoinflammatory disease. N Engl J Med. 2020;383:2628–38.
https://doi.org/10.1056/NEJMoa2026834.
48. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH,
Zhang Y, et al. Autoantibodies against type I IFNs in patients with
life-threatening COVID-19. Science. 2020;370(6515):eabd4585.
https://doi.org/10.1126/science.abd4585.
49. Pohl E, Aykut A, Beleggia F, Karaca E, Durmaz B, Keupp K, et al.
A hypofunctional PAX1 mutation causes autosomal recessively
inherited otofaciocervical syndrome. Hum Genet. 2013;132(11):
1311–20. https://doi.org/10.1007/s00439-013-1337-9.
50. Spencer S, Kostel Bal S, Egner W, Lango Allen H, Raza SI, Ma
CA, et al. Loss of the interleukin-6 receptor causes immunodefi-
ciency, atopy, and abnormal inflammatory responses. J Exp Med.
2019;216(9):1986–98. https://doi.org/10.1084/jem.20190344.
51. Gombart AF, Koeffler HP. Neutrophil specific granule deficiency
and mutations in the gene encoding transcription factor
C/EBP(epsilon). Curr Opin Hematol. 2002;9(1):36–42. https://doi.
org/10.1097/00062752-200201000-00007.
52. Su HC, Orange JS. The growing spectrum of human diseases
caused by inherited CDC42 mutations. J Clin Immunol.
2020;40(4):551–3. https://doi.org/10.1007/s10875-020-00785-8.
53. Hambleton S, Goodbourn S, Young DF, Dickinson P, Mohamad
SM, Valappil M, et al. STAT2 deficiency and susceptibility to viral
illness in humans. Proc Natl Acad Sci U S A. 2013;110(8):3053–8.
https://doi.org/10.1073/pnas.1220098110.
54. Moens L, Van Eyck L, Jochmans D, Mitera T, Frans G, Bossuyt X,
et al. A novel kindred with inherited STAT2 deficiency and severe
viral illness. J Allergy Clin Immunol. 2017;139(6):1995–7 e9.
https://doi.org/10.1016/j.jaci.2016.10.033.
55. Cuchet-Lourenco D, Eletto D, Wu C, Plagnol V, Papapietro O,
Curtis J, et al. Biallelic RIPK1 mutations in humans cause severe
immunodeficiency, arthritis, and intestinal inflammation. Science.
2018;361(6404):810–3. https://doi.org/10.1126/science.aar2641.
56. Li Y, Fuhrer M, Bahrami E, Socha P, Klaudel-Dreszler M, Bouzidi
A, et al. Human RIPK1 deficiency causes combined immunodefi-
ciency and inflammatory bowel diseases. Proc Natl Acad Sci U S
A. 2019;116(3):970–5. https://doi.org/10.1073/pnas.1813582116.
57. Casanova JL, Conley ME, Seligman SJ, Abel L, Notarangelo LD.
Guidelines for genetic studies in single patients: lessons from pri-
mary immunodeficiencies. J Exp Med. 2014;211(11):2137–49.
https://doi.org/10.1084/jem.20140520.
58. Bustamante J. Mendelian susceptibility to mycobacterial disease:
recent discoveries. Hum Genet. 2020;139(6–7):993–1000. https://
doi.org/10.1007/s00439-020-02120-y.
59. Moens L, Meyts I. Recent human genetic errors of innate immunity
leading to increased susceptibility to infection. Curr Opin Immunol.
2020;62:79–90. https://doi.org/10.1016/j.coi.2019.12.002.
60. Zhang SY. Herpes simplex virus encephalitis of childhood: inborn
errors of central nervous system cell-intrinsic immunity. Hum
Genet. 2020;139(6–7):911–8. https://doi.org/10.1007/s00439-020-
02127-5.
61. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of hu-
man JAKs and STATs. Immunity. 2012;36(4):515–28. https://doi.
org/10.1016/j.immuni.2012.03.016.
62. Shahin T, Aschenbrenner D, Cagdas D, Bal SK, Conde CD,
Garncarz W, et al. Selective loss of function variants in IL6ST
cause hyper-IgE syndrome with distinct impairments of T-cell phe-
notype and function. Haematologica. 2019;104(3):609–21. https://
doi.org/10.3324/haematol.2018.194233.
63. Nahum A, Sharfe N, Broides A, Dadi H, Naghdi Z, Mandola AB,
et al. Defining the biological responses of IL-6 by the study of a
novel IL-6 receptor chain immunodeficiency. J Allergy Clin
Immunol. 2020;145(3):1011–5 e6. https://doi.org/10.1016/j.jaci.
2019.11.015.
64. Puel A, Picard C, Lorrot M, Pons C, Chrabieh M, Lorenzo L, et al.
Recurrent staphylococcal cellulitis and subcutaneous abscesses in a
child with autoantibodies against IL-6. J Immunol. 2008;180(1):
647–54. https://doi.org/10.4049/jimmunol.180.1.647.
65. Martinez-Barricarte R, Markle JG, Ma CS, Deenick EK, Ramirez-
Alejo N, Mele F, et al. Human IFN-gamma immunity to
mycobacteria is governed by both IL-12 and IL-23. Sci Immunol.
2018;3(30):eaau6759. https://doi.org/10.1126/sciimmunol.
aau6759.
66. Kotlarz D, Zietara N,Milner JD, Klein C. Human IL-21 and IL-21R
deficiencies: two novel entities of primary immunodeficiency. Curr
Opin Pediatr. 2014;26(6):704–12. https://doi.org/10.1097/MOP.
0000000000000160.
67. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J,
et al. Inborn errors of type I IFN immunity in patients with life-
threatening COVID-19. Science. 2020;370(6515):eabd4570.
https://doi.org/10.1126/science.abd4570.
68. Zhang Q. Human genetics of life-threatening influenza pneumoni-
tis. Hum Genet. 2020;139(6–7):941–8. https://doi.org/10.1007/
s00439-019-02108-3.
69. Ku CL, Chi CY, von Bernuth H, Doffinger R. Autoantibodies
against cytokines: phenocopies of primary immunodeficiencies?
Hum Genet. 2020;139(6–7):783–94. https://doi.org/10.1007/
s00439-020-02180-0.
70. Levy R, Bastard P, Lanternier F, Lecuit M, Zhang SY, Casanova
JL. IFN-alpha2a therapy in two patients with inborn errors of TLR3
and IRF3 infected with SARS-CoV-2. J Clin Immunol. 2021;41:
26–7. https://doi.org/10.1007/s10875-020-00933-0.
Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
678 J Clin Immunol  (2021) 41:666–679
Affiliations
Stuart G. Tangye1,2 &Waleed Al-Herz3 & Aziz Bousfiha4 & Charlotte Cunningham-Rundles5 & Jose Luis Franco6 &
Steven M Holland7 &Christoph Klein8 & Tomohiro Morio9 & Eric Oksenhendler10 &Capucine Picard11,12 &Anne Puel13,14 &
Jennifer Puck15 &Mikko R. J. Seppänen16 & Raz Somech17 & Helen C Su7 & Kathleen E. Sullivan18 & Troy R. Torgerson19 &
Isabelle Meyts20
1 Garvan Institute of Medical Research, Darlinghurst, Sydney, New
South Wales 2010, Australia
2 Faculty of Medicine, St Vincent’s Clinical School, UNSW Sydney,
Sydney, NSW, Australia
3 Department of Pediatrics, Faculty of Medicine, Kuwait University,
Kuwait City, Kuwait
4 Laboratoire d’Immunologie Clinique, d’Inflammation et d’Allergy
LICIA Clinical Immunology Unit, Casablanca Children’s Hospital,
Ibn Rochd Medical School, King Hassan II University,
Casablanca, Morocco
5 Departments of Medicine and Pediatrics, Mount Sinai School of
Medicine, New York, NY, USA
6 Grupo de Inmunodeficiencias Primarias, Facultad de Medicina,
Universidad de Antioquia UdeA, Medellin, Colombia
7 Laboratory of Clinical Immunology & Microbiology, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, MD, USA
8 Dr von Hauner Childrens Hospital, Ludwig-Maximilians-University
Munich, Munich, Germany
9 Department of Pediatrics and Developmental Biology, Tokyo
Medical and Dental University, Tokyo, Japan
10 Department of Clinical Immunology, Hôpital Saint-Louis, APHP,
University Paris Diderot, Sorbonne Paris Cité, Paris, France
11 Study Center for Primary Immunodeficiencies, Necker Hospital for
Sick Children, APHP, Paris, France
12 Laboratory of Lymphocyte Activation and Susceptibility to EBV,
INSERM UMR1163, Imagine Institute, Necker Hospital for Sick
Children, Paris University, Paris, France
13 Laboratory of Human Genetics of Infectious Diseases, INSERM
U1163, Necker Hospital, 75015 Paris, France
14 Imagine Institute, University of Paris, 75015 Paris, France
15 Department of Pediatrics, University of California San Francisco
and UCSF Benioff Children’s Hospital, San Francisco, CA, USA
16 Adult Immunodeficiency Unit, Infectious Diseases, Inflammation
Center and Rare Diseases Center, Childrens Hospital, University of
Helsinki and Helsinki University Hospital, Helsinki, Finland
17 Pediatric Department and Immunology Unit, Sheba Medical
Center, Tel Aviv, Israel
18 Division of Allergy Immunology, Department of Pediatrics,
Childrens Hospital of Philadelphia, University of Pennsylvania
Perelman School of Medicine, Philadelphia, PA, USA
19 Allen Institute for Immunology, Seattle, WA, USA
20 Department of Immunology and Microbiology, Laboratory for
Inborn Errors of Immunity, Department of Pediatrics, University
Hospitals Leuven and KU Leuven, 3000 Leuven, Belgium
679J Clin Immunol  (2021) 41:666–679
